All in pfizer.....Stock of the-To The Moon - Tiger Brokers Online Investing Community - To The Moon

5
Comment
Favorite

Skyzero9285
2022-06-30

All in pfizer.....Stock of the year💪🏼👏🏼👏🏼👏🏼👏🏼🚀

Pfizer Files for Full FDA Approval for COVID-19 Antiviral

Pfizer Inc. $(PFE)$ said Thursday that it has submitted a New Drug Application (NDA) for COVID-19 tr

Pfizer Files for Full FDA Approval for COVID-19 Antiviral

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

5

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":9045174255,"tweetId":"9045174255","gmtCreate":1656588138377,"gmtModify":1676535858645,"author":{"id":3574635585550746,"idStr":"3574635585550746","authorId":3574635585550746,"authorIdStr":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":1,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.15","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>All in pfizer.....Stock of the year💪🏼👏🏼👏🏼👏🏼👏🏼🚀</p></body></html>","htmlText":"<html><head></head><body><p>All in pfizer.....Stock of the year💪🏼👏🏼👏🏼👏🏼👏🏼🚀</p></body></html>","text":"All in pfizer.....Stock of the year💪🏼👏🏼👏🏼👏🏼👏🏼🚀","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/9045174255","repostId":2247475886,"repostType":2,"repost":{"id":"2247475886","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1656587274,"share":"https://www.laohu8.com/m/news/2247475886?lang=&edition=full","pubTime":"2022-06-30 19:07","market":"us","language":"en","title":"Pfizer Files for Full FDA Approval for COVID-19 Antiviral","url":"https://stock-news.laohu8.com/highlight/detail?id=2247475886","media":"Dow Jones","summary":"Pfizer Inc. $(PFE)$ said Thursday that it has submitted a New Drug Application (NDA) for COVID-19 tr","content":"<html><head></head><body><p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> said Thursday that it has submitted a New Drug Application (NDA) for COVID-19 treatment pills PAXLOVID for patients at high risk for progression to severe illness.</p><p>PAXLOVID has previously been granted Emergency Use Authorization <a href=\"https://laohu8.com/S/EUA.UK\">$(EUA.UK)$</a> for treatment of mild-to-moderate COVID-19. The drug maker said the NDA submission provides longer-term follow-up data needed for potential approval.</p><p>&#34;Data from our clinical development program, coupled with the more than 1.7 million patients around the world who have been prescribed our oral treatment to date, reinforce PAXLOVID as an important treatment option for mild-to-moderate COVID-19 in patients at greater risk of progression to severe symptoms, regardless of vaccination status,&#34; said Pfizer Chief Executive Albert Bourla.</p><p>The stock, which slipped 0.5% in premarket trading, has lost 13.7% year to date through Wednesday, while the S&amp;P 500  has climbed 19.9%.</p><p><img src=\"https://static.tigerbbs.com/5f5463ed1aa0fa37ef029aec1dd2eea6\" tg-width=\"842\" tg-height=\"830\" referrerpolicy=\"no-referrer\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Files for Full FDA Approval for COVID-19 Antiviral</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Files for Full FDA Approval for COVID-19 Antiviral\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2022-06-30 19:07</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> said Thursday that it has submitted a New Drug Application (NDA) for COVID-19 treatment pills PAXLOVID for patients at high risk for progression to severe illness.</p><p>PAXLOVID has previously been granted Emergency Use Authorization <a href=\"https://laohu8.com/S/EUA.UK\">$(EUA.UK)$</a> for treatment of mild-to-moderate COVID-19. The drug maker said the NDA submission provides longer-term follow-up data needed for potential approval.</p><p>&#34;Data from our clinical development program, coupled with the more than 1.7 million patients around the world who have been prescribed our oral treatment to date, reinforce PAXLOVID as an important treatment option for mild-to-moderate COVID-19 in patients at greater risk of progression to severe symptoms, regardless of vaccination status,&#34; said Pfizer Chief Executive Albert Bourla.</p><p>The stock, which slipped 0.5% in premarket trading, has lost 13.7% year to date through Wednesday, while the S&amp;P 500  has climbed 19.9%.</p><p><img src=\"https://static.tigerbbs.com/5f5463ed1aa0fa37ef029aec1dd2eea6\" tg-width=\"842\" tg-height=\"830\" referrerpolicy=\"no-referrer\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BK4017":"黄金","BK4548":"巴美列捷福持仓","BNTX":"BioNTech SE","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4535":"淡马锡持仓","BK4550":"红杉资本持仓","BK4581":"高盛持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","BK4007":"制药","BK4570":"地缘局势概念股","NGD":"New Gold","BK4551":"寇图资本持仓"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2247475886","content_text":"Pfizer Inc. $(PFE)$ said Thursday that it has submitted a New Drug Application (NDA) for COVID-19 treatment pills PAXLOVID for patients at high risk for progression to severe illness.PAXLOVID has previously been granted Emergency Use Authorization $(EUA.UK)$ for treatment of mild-to-moderate COVID-19. The drug maker said the NDA submission provides longer-term follow-up data needed for potential approval.\"Data from our clinical development program, coupled with the more than 1.7 million patients around the world who have been prescribed our oral treatment to date, reinforce PAXLOVID as an important treatment option for mild-to-moderate COVID-19 in patients at greater risk of progression to severe symptoms, regardless of vaccination status,\" said Pfizer Chief Executive Albert Bourla.The stock, which slipped 0.5% in premarket trading, has lost 13.7% year to date through Wednesday, while the S&P 500  has climbed 19.9%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":546,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":52,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}